Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

- PMLiVE

Novartis’ Bexsero triumphs at UK Prix Galien

The Awards also saw Janssen's Sirturo pick up the Orphan Drug prize

- PMLiVE

EMA to review experimental Ebola drugs

Response comes as death-toll tops 3,000

- PMLiVE

EMA wants to embed patient viewpoint within drug assessment

Will pilot CHMP benefit-risk evaluation project

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Boehringer Ingelheim promotes Debraj Dasgupta

He will lead on its global marketing and sales platforms

- PMLiVE

Novartis expands eyecare partnership with NHS

And wins new licence for Lucentis

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

FDA panel votes against Actavis hypertension combo

Places a question mark over the combination of Bystolic and Diovan

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links